{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:54:30Z","timestamp":1782903270681,"version":"3.54.5"},"reference-count":128,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2020,11,1]]},"DOI":"10.1080\/13543776.2020.1811854","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T08:17:06Z","timestamp":1598429826000},"page":"847-862","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Repositioning and investigational drugs for Zika virus infection treatment: a patent review"],"prefix":"10.1080","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5644-7181","authenticated-orcid":false,"given":"Sandro","family":"G. Viveiros Rosa","sequence":"first","affiliation":[{"name":"Diretoria de Patentes, Divis\u00e3o De Farm\u00e1cia - Instituto Nacional Da Propriedade Industrial, Rio de Janeiro, Brasil"},{"name":"Programa De P\u00f3s-Gradua\u00e7\u00e3o Em Ci\u00eancias Aplicadas a Produtos Para Sa\u00fade, Faculdade De Farm\u00e1cia, Universidade Federal Fluminense, Brasil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda M.","family":"Fierro","sequence":"additional","affiliation":[{"name":"cAcademia De Propriedade Intelectual - Instituto Nacional Da Propriedade Industrial, Rio de Janeiro, Niteroi City, Rio de Janeiro, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9971-094X","authenticated-orcid":false,"given":"Wilson","family":"C. Santos","sequence":"additional","affiliation":[{"name":"Programa De P\u00f3s-Gradua\u00e7\u00e3o Em Ci\u00eancias Aplicadas a Produtos Para Sa\u00fade, Faculdade De Farm\u00e1cia, Universidade Federal Fluminense, Brasil;"},{"name":"dInstituto Te\u00f3filo Hernando, Departamento De Farmacolog\u00eda, Facultad De Medicina, Universidad Aut\u00f3noma De Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"cit0001","unstructured":"WHO. R & D blueprint list of blueprint priority diseases; 2018 1\u20133 [cited 2020 Jul 19]. Available from: http:\/\/origin.who.int\/blueprint\/priority-diseases\/en\/"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00279-16"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1038\/s41559-019-0836-z"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.26633\/RPSP.2020.7"},{"key":"cit0005","first-page":"509","volume":"46","author":"Dick GWA","year":"1952","journal-title":"Notes Queries"},{"key":"cit0006","unstructured":"Pan American Health Organization\/World Health Organization. Zika suspected and confirmed cases reported by countries and territories in the Americas cumulative cases, 2015\u20132017. Washington, D.C.: PAHO\/WHO; 2017 [Updated 2017 Dec 21; cited 2020 Jul 19]. Available from: https:\/\/www.paho.org\/hq\/dmdocuments\/2017\/2017-dec-21-phe-ZIKV-cases.pdf"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2016.09.012"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2019.04.005"},{"key":"cit0009","first-page":"e2017473","volume":"27","author":"Fran\u00e7a GVA","year":"2018","journal-title":"Epidemiol Serv Sa\u00fade"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2018.06.014"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2016.07.004"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.9b00933"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1080\/1062936X.2017.1411642"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25031"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.01469"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2016.09.006"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00411-17"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4184"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2016.01.012"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.respol.2016.02.006"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.168"},{"key":"cit0022","first-page":"360","volume":"342","author":"Shaughnessy A","year":"2011","journal-title":"Drug Dev"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1038\/d41587-020-00003-1"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.26633\/RPSP.2020.40"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2001.00803.x"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.02.198"},{"key":"cit0027","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02662855"},{"key":"cit0028","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02329054"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001967"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.11.013"},{"key":"cit0031","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01227421"},{"key":"cit0032","first-page":"1","volume":"6","author":"Tran MN","year":"2018","journal-title":"Respirol Case Rep"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3180"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.wpi.2005.05.003"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.wpi.2008.07.002"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1186\/s40552-015-0007-y"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1080\/0194262X.2018.1431589"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005132"},{"key":"cit0039","first-page":"95","volume":"14","author":"Marano G","year":"2016","journal-title":"Blood Transfusion"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2019.01.005"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201695871"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1126\/science.aai9309"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1039\/C6RA12142J"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120231"},{"key":"cit0045","unstructured":"Souza TML, Andrade NB, Bozza PT, et al. Composto antiviral, composi\u00e7\u00e3o farmac\u00eautica antiviral, uso do composto e m\u00e9todo de tratamento. BR 102016012517 A2. 2016."},{"key":"cit0046","unstructured":"Souza TML, Andrade NB, Bozza PT, et al. Composto antiviral, composi\u00e7\u00e3o farmac\u00eautica antiviral, uso do composto e m\u00e9todo de Tratamento. BR 102017011488 A2. 2017."},{"key":"cit0047","unstructured":"Junior LHGF, Freitas CBMH, Pilger DRB. Composi\u00e7\u00e3o farmac\u00eautica para o tratamento de infec\u00e7\u00e3o causada por v\u00edrus da fam\u00edlia flaviviridae, e, uso da composi\u00e7\u00e3o. BR 102017028623-1 A2. 2017"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.31768\/2312-8852.2016.38(1):2-8"},{"key":"cit0049","unstructured":"Hodge TW. Treatment or prevention of zika virus infections by administration of a ribonuclease. WO 2017\/142807 A1. 2017."},{"key":"cit0050","unstructured":"Tang H, Lee EM, Cheng Y, et al. Compounds and methods for treatment and prevention of flavivirus infection. US 20180015153 A1. 2016."},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2017.04.001"},{"key":"cit0052","unstructured":"Shibo J, Xiaohuan W, Lu ZP. Use of erythromycin in the preparation of medicines for specifically inhibiting viral infections. CN 111317739 A. 2018."},{"key":"cit0053","unstructured":"Li H, Kramer LD, Li ZH, et al. Pharmaceutical compositions with antiflaviviral activity. WO 2017\/223491 A1. 2017."},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.3390\/nano8100847"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767130-00015"},{"key":"cit0056","unstructured":"Rana TM. Methods for treating flaviviruses and zika infections. WO 2018\/136559 A1. 2018."},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13793"},{"key":"cit0058","unstructured":"Yuan S, Chan FWJ, Yuen KY, et al. Zika virus protease inhibitors and methods of use thereof. WO 2018\/192083 A1. 2018."},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.7b07736"},{"key":"cit0060","doi-asserted-by":"crossref","unstructured":"Brass AL. Inhibition of zika virus infection. 214080 A1. 2017.","DOI":"10.1016\/j.seizure.2016.11.004"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2014.60"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.04.017"},{"key":"cit0063","unstructured":"Shinya H, Nagayoshi K, Takashi K, et al. Pharmaceutical composition for treatment of zika virus infection. JP 2018076280A. 2018."},{"key":"cit0064","doi-asserted-by":"crossref","unstructured":"Babu YS, Kotian PL, Bantia S. Methods and compositions for treatment of zika virus infection. WO 2017\/155886 A1. 2017.","DOI":"10.1016\/j.seizure.2016.11.004"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0179-7"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2017.1255725"},{"key":"cit0067","unstructured":"Du J, Nagarathnam D, Sofia MJ, et al. Nucleoside phosphoramidate prodrugs. WO 2008\/121634 A2. 2008."},{"key":"cit0068","unstructured":"Cihlar T, Clarke M, Jordan R, et al. Methods for treating zika virus infections. WO 2017\/184670 A2. 2017."},{"key":"cit0069","unstructured":"Clarke M, Jordan R, Mack-Man RL, et al. Methods for treatingflaviriridaevirus infections. WO2017\/184668 A1. 2017."},{"key":"cit0070","unstructured":"Li M, Yu J, Yuan J, et al. Application of Fidaxomicin in preparation of medicines treating related diseases and\/or symptoms caused by Zika virus infection. CN 107737133 A. 2018."},{"key":"cit0071","unstructured":"Cao J, Guo J, Jia X, et al. Use of digoxin in preparation of medicament for treating mammal flavivirus infection. CN 108619164 A. 2018."},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1038\/srep46134"},{"key":"cit0073","unstructured":"Drugs.com. Lanatoside C [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/www.drugs.com\/international\/lanatoside-c.html"},{"key":"cit0074","unstructured":"Prendergast P. Antiviral compound and analogues thereof for treatment or prevention of flavivirus dengue\/zika infections. US 2017\/0348330 A1. 2017."},{"key":"cit0075","unstructured":"Jiang S, Lu LZP. Application of Montelukast sodium in inhibiting infection of Zika virus, dengue virus and yellow fever virus. CN 106983750 A. 2017."},{"key":"cit0076","unstructured":"Jiang S, Lu L, Zou P. Small molecular drug capable of being used for inhibiting Zika virus infection and application of drug. CN 106511346 A. 2017."},{"key":"cit0077","first-page":"135","volume":"51","author":"Fanunza E","year":"2018","journal-title":"Annu Rep Med Chem"},{"key":"cit0078","unstructured":"Trestom AM, Warfield KL. Methods of treating zika virus infection. WO 2017\/201052 Al. 2017."},{"key":"cit0079","unstructured":"Tang H, Lee EM, Tharappel AM, et al. Emetine compounds for treatment and prevention of flavivirus infection. WO 2019\/075011 A1. 2019."},{"key":"cit0080","unstructured":"Li H, Xiong R, Xu K, et al. Novel antiviral medicines and application thereof. CN 108721281 A. 2018."},{"key":"cit0081","unstructured":"Khalil K. Antiflaviviridae activity of anti-retroviral non-nucleoside (NNRTIS) and nucleoside reverse transcriptase inhibitors (NNRTIS). WO 2018\/119371 A1. 2018."},{"key":"cit0082","unstructured":"Chengfeng Q, Xi Z, Baoyang H, et al. Enoxacin in the prevention and\/or treatment of flavivirus infection. CN 111214472 A. 2018."},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.14.8698-8706.2005"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.12.008"},{"key":"cit0085","unstructured":"U.S. National Library of medicine. Clinical Trials.gov [Internet]; [cited 2020 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00292084?term=NCT00292084&draw=2&rank=1"},{"key":"cit0086","unstructured":"Holmes E, Ostrander G. Treatment of Zika virus infections using alpha-glucosidase inhibitors. US 20180117018 A1. 2018."},{"key":"cit0087","unstructured":"Holmes E, Ostrander G. Treatment of Zika virus infections using alpha-glucosidase inhibitors. 20170312257 A1. 2018."},{"key":"cit0088","unstructured":"Choi SH, Kim DM, Lim HJ, et al. Pharmaceutical composition for preventing or treating zika virus. KR 20170125484 A. 2017."},{"key":"cit0089","unstructured":"Ke C, Liu H, Liu S, et al. Application of epigallocatechin gallate and derivatives thereof in preparing drugs for resisting against zika virus. CN 109674785 A. 2019."},{"key":"cit0090","unstructured":"Min Z, Hongmiao L, Xingang, et al. Quercetin and its derivative are preparing the application in anti-Zika virus drug. CN109674780. 2019."},{"key":"cit0091","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02580279?term=NCT02580279&draw=2&rank=1"},{"key":"cit0092","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02577393?term=NCT02577393&draw=2&rank=1"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.04.006"},{"key":"cit0094","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03943459"},{"key":"cit0095","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04063124?term=NCT04063124&draw=2&rank=1"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12570"},{"key":"cit0097","unstructured":"Chen J, Duan Y, Ji R, et al. Novel application of IFN-lambda in Zika virus infection. CN 107412739 A. 2017."},{"key":"cit0098","unstructured":"Lai X, Lao Z, Li G, et al. Application of baicalin in preparation of medicine for preventing and treating Zika virus infection. CN 107823215 A. 2018."},{"key":"cit0099","unstructured":"Lai X, Lao Z, Li G, et al. Application of baicalin in preparation of drug for preventing and treating Zika virus infection. CN 109453158 A. 2019."},{"key":"cit0100","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03830684?term=NCT03830684&draw=2&rank=1"},{"key":"cit0101","doi-asserted-by":"crossref","unstructured":"Rosen BD Alternative ACT with natural botanical active GRAS ingredients for treatment and prevention of the ZIKA virus. US 9675582 A1. 2016.","DOI":"10.1155\/2016\/2965214"},{"key":"cit0102","unstructured":"Feng C, He P, Tang W, et al. Application of andrographolide or derivatives thereof in preparation of Zika virus inhibitor drug. CN 108619133 A. 2018."},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0595-2"},{"key":"cit0104","unstructured":"Michel C, Majambu M, Xiang Guo Q, et al. Methods of preventing or treating filovirus and flavivirus diseases. US 2018\/0353528 A1. 2018."},{"key":"cit0105","unstructured":"Tang H, Lee EM, Zheng W, et al. Anti-flavivirus compounds and methods of use. US 20200197369 A1. 2018."},{"key":"cit0106","first-page":"4205","volume":"6","author":"Vaishampayan U","year":"2000","journal-title":"Clin Cancer Res"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h3429"},{"key":"cit0108","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03624946"},{"key":"cit0109","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03443830?cond=NCT03443830&draw=2&rank=1"},{"key":"cit0110","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03425149"},{"key":"cit0111","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02996461"},{"key":"cit0112","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03110770"},{"key":"cit0113","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02840487"},{"key":"cit0114","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03008122"},{"key":"cit0115","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02963909"},{"key":"cit0116","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02952833"},{"key":"cit0117","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02937233"},{"key":"cit0118","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]. [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02996890"},{"key":"cit0119","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03611946"},{"key":"cit0120","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03055000"},{"key":"cit0121","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02809443"},{"key":"cit0122","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02887482"},{"key":"cit0123","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03343626"},{"key":"cit0124","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03014089"},{"key":"cit0125","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=NCT04064905+&cntry=&state=&city=&dist="},{"key":"cit0126","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03158233?term=NCT03158233&draw=2&rank=1"},{"key":"cit0127","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04015648?term=NCT04015648&draw=2&rank=1"},{"key":"cit0128","unstructured":"U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [cited 2020 Jul 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04033068?term=NCT04033068&draw=2&rank=1"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2020.1811854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:58:05Z","timestamp":1668041885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2020.1811854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":128,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11,1]]}},"alternative-id":["10.1080\/13543776.2020.1811854"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2020.1811854","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-04-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}